Follow
Neill Liptrott
Neill Liptrott
Professor, Department of Pharmacology & Therapeutics, ISMIB, University of Liverpool
Verified email at liv.ac.uk - Homepage
Title
Cited by
Cited by
Year
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms
RC Hartkoorn, W San Kwan, V Shallcross, A Chaikan, N Liptrott, D Egan, ...
Pharmacogenetics and genomics 20 (2), 112-120, 2010
2192010
Prioritization of anti‐SARS‐Cov‐2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics
U Arshad, H Pertinez, H Box, L Tatham, RKR Rajoli, P Curley, M Neary, ...
Clinical Pharmacology & Therapeutics 108 (4), 775-790, 2020
1542020
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction
SP Pushpakom, NJ Liptrott, S Rodríguez-Nóvoa, P Labarga, V Soriano, ...
Journal of Infectious Diseases 204 (1), 145-153, 2011
1402011
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC
NJ Liptrott, M Penny, PG Bray, J Sathish, SH Khoo, DJ Back, A Owen
British journal of pharmacology 156 (3), 497-508, 2009
972009
Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro–in vivo correlation
TO McDonald, M Giardiello, P Martin, M Siccardi, NJ Liptrott, D Smith, ...
Advanced healthcare materials 3 (3), 400-411, 2014
932014
Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir
DM Moss, WS Kwan, NJ Liptrott, DL Smith, M Siccardi, SH Khoo, DJ Back, ...
Antimicrobial agents and chemotherapy 55 (2), 879-887, 2011
712011
Immunotoxicity considerations for next generation cancer nanomedicines
G Hannon, J Lysaght, NJ Liptrott, A Prina‐Mello
Advanced Science 6 (19), 1900133, 2019
662019
Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis
RKR Rajoli, H Pertinez, U Arshad, H Box, L Tatham, P Curley, M Neary, ...
British Journal of Clinical Pharmacology 87 (4), 2078-2088, 2021
622021
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS
NJ Liptrott, S Pushpakom, C Wyen, G Fätkenheuer, C Hoffmann, S Mauss, ...
Pharmacogenetics and genomics 22 (1), 10-19, 2012
61*2012
Functionalized superparamagnetic iron oxide nanoparticles provide highly efficient iron-labeling in macrophages for magnetic resonance–based detection in vivo
J Sharkey, PJS Lewis, M Barrow, SM Alwahsh, J Noble, E Livingstone, ...
Cytotherapy 19 (4), 555-569, 2017
542017
Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies
M Giardiello, NJ Liptrott, TO McDonald, D Moss, M Siccardi, P Martin, ...
Nature communications 7 (1), 13184, 2016
542016
Bridging communities in the field of nanomedicine
B Halamoda-Kenzaoui, S Baconnier, T Bastogne, D Bazile, P Boisseau, ...
Regulatory Toxicology and Pharmacology 106, 187-196, 2019
412019
Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation
P Curley, RKR Rajoli, DM Moss, NJ Liptrott, S Letendre, A Owen, ...
Antimicrobial agents and chemotherapy 61 (1), 10.1128/aac. 01841-16, 2017
402017
Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines
M Rösslein, NJ Liptrott, A Owen, P Boisseau, P Wick, IK Herrmann
Nanotoxicology 11 (2), 147-149, 2017
392017
Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 In Vitro
DM Moss, NJ Liptrott, P Curley, M Siccardi, DJ Back, A Owen
Antimicrobial agents and chemotherapy 57 (11), 5612-5618, 2013
382013
Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation
B Halamoda-Kenzaoui, RJ Vandebriel, A Howarth, M Siccardi, ...
Journal of Controlled Release 336, 192-206, 2021
362021
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals
A Jackson, V Watson, D Back, S Khoo, N Liptrott, D Egan, K Gedela, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 58 (5), 450-457, 2011
352011
Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies
P Urbán, NJ Liptrott, S Bremer
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 11 (3 …, 2019
342019
Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches
CAW David, A Owen, NJ Liptrott
Nanomedicine 11 (11), 1447-1464, 2016
342016
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients
J Moltó, M Valle, D Back, S Cedeno, V Watson, N Liptrott, D Egan, ...
Antimicrobial agents and chemotherapy 55 (1), 72-75, 2011
322011
The system can't perform the operation now. Try again later.
Articles 1–20